Holmes RS, et al. - Researchers evaluated evidence comparing the benefits and harms of long-acting insulins in patients with type 1 and 2 diabetes by searching MEDLINE and two Cochrane databases through February 2018. For this systematic review and meta-analysis, they included comparative studies of adult or paediatric patients with diabetes treated with insulin degludec, detemir or glargine. According to findings, there were no differences in glycaemic control between insulin degludec, detemir and glargine. Degludec was less likely to cause hypoglycemia than glargine. Detemir-treated adults gained approximately 1 kg less body weight than degludec (type 1) or glargine (type 2). In patients with type 2 diabetes, withdrawals were more likely with detemir than with glargine because of adverse events. Between any two insulins or formulations, they did not observe any statistically significant differences in hemoglobin A1c.